Our studies

Scientific studies have to be elaborated, planed and conducted meticulously. This is the only way to receive significant results and answers. And it is the only way how the Biogena Scientific Team could – and can, together with partners (physicians) and external scientists, generate remarkable evidences for the efficacy of micronutrients.


The enzyme-study

Enzymes are proteins that play an important role in digestion. But some enzymes have even more capabilities and can become active in our body, for example in fighting pain. The Biogena Scientific Team, lead by the orthopaedic specialist Dr. Frank Düren, conducted research as to if certain enzymes can positively influence non-specific back pain.

Scientific background
Already in the 1950s, physician Prof. Dr. Max Wolf and biologist Dr. Karl Ransberger could prove scientifically that certain proteins – for example derived from pineapple or papaya (bromelain and papain) – can accelerate healing of wounds with inflammations. This was the beginning of the systemic enzyme therapy that is – nowadays worldwide - used for injuries, for accelerating healing processes after surgery, for rheumatic complaints, for all kinds of inflammations and in oncology as complementary therapy.

The Biogena Scientific Team wanted to know whether a combination of certain enzymes, together with other substances, helps in the case of non-specific back pain. This pain is often a considerable and long-term impairment for the quality of life of patients.

The tested preparation
The tested supplement was Biogena preparation DoloZym® forte Gold with proteolytic enzymes (bromelain, papain, trypsin, chymotrypsin) and bioflavonoids (quercetin and bioflavonoids derived from citrus and grape seeds).

The method
This study comprised 46 patients suffering from non-specific back pain that attended voluntarily. To start with, the Scientific Team determined the degree of movement limitation and limitation in daily life. The Oswestry Low Back Pain Questionnaire that was used is internationally accepted and applied in clinical studies. It helps collect data such as pain when walking, standing, lifting, sitting or limitations in travelling or sleeping. Since back pain is often accompanied by depression, the WHO-5 Well-Being Index that determines signs of depression was used additionally.

The test persons were grouped at random: 25 participants took DoloZym® forte Gold, 21 participants took placebo capsules containing no active substance filled with cellulose. After 4 weeks of taking 2 x 3 capsules per day (on an empty stomach), the Scientific Team again determined the degree of limitation by means of the Oswestry Questionnaire and well-being as well as signs of depression by means of the WHO-5 Index. Data of 33 participants (17 participants taking DoloZym® forte Gold, 16 participants belonging to the placebo group) could be evaluated.

The result

  • The statistical analysis of the data showed a significant effect of the preparation Biogena DoloZym® forte Gold compared to a placebo. The total score for “back pain-related limitations in daily activities” improved by 27,2 % for those participants of the group that used DoloZym® forte Gold over a period of 4 weeks, whereas it deteriorated by 12,3 % in the participants of the placebo group.
  • Pain reduced by 26,5 % in the enzyme group, but remained unchanged in the placebo group. Concerning quality of sleep, the impairments reduced by 26,8 % in the enzyme group and remained unchanged in the placebo group.
  • As far as depression is concerned, there were signs of depression in 23 of the 33 evaluated participants (70 %) at the beginning of the study. By taking DoloZym® forte Gold, the proportion of persons showing signs of depression reduced by 60 % (from 10 to 4 participants), in the placebo group only by 30,7 % (from 13 to 9 persons).
  • This study shows that the use of a dietary preparation with natural enzymes can significantly reduce back pain-related limitations in daily activities.


The authors of the study
Director of the study: Dr. med. Frank Düren, orthopaedic specialist, D-83224 Grassau
Dr. Ina Viebahn, nutritionist Biogena Scientific Team, coordination scientific studies
Barbara Fäth-Neubauer (Dipl. oec. troph. Univ.) nutritionist, Director of Biogena Scientific Team



The Griffonia-study


Griffonia simplicifolia is the scientific name of an African bean. In Africa, it has been used for ages as moodlifter and aphrodisiac. Therefore, the Biogena Scientific Team under the direction of the general practitioner Dr. Walter Wührer (Salzburg) examined the effect of Griffonia in the case of depressive moods, anxiety disorders and stress.

Scientific background
Griffonia simplicifolia is closely connected to the ”happy hormone“ serotonin. 5-Hydroxytryptophan (5-HTP), a natural amino acid that is transformed into the hormone serotonin in our organism, is derived from Griffonia. This means that Griffonia is a preliminary stage of serotonin. We know about this hormone that it influences our mood, which is why it is popularly known as “the happy hormone”. Serotonin levels that are sufficiently high are closely connected to feelings of satisfaction and reduced anxiety, whereas depressive moods and anxiety states are often linked to serotonin deficiencies.

The tested preparation
Biogena went one step further and wanted to know, whether the 5-HTP that is contained in Griffonia – combined with several B-vitamins, a combination like in the Biogena product Griffonia50 Serolution® - is effective in the case of depressive moods, slight anxiety states and stress.

The method
For this purpose, 69 persons showing signs of depression, anxiety or heavy stress could be recruited as participants in this study through physicians that are partners of Biogena. One group used Biogena Griffonia50 Serolution® (2 capsules a day) over a period of three weeks, the other group (placebo group) used cellulose capsules that contained no active substance. Naturally, the participants did not know whether they belonged to the Griffonia- or the placebo group. At the beginning and at the end of the study, the probands were tested for depression, anxiety and stress by means of the DASS-Scale (Depression, Anxiety, Stress Scales) that is used internationally.

The result

  • In all three categories, the tested preparation did significantly better than the placebo (the cellulose capsules).
  • In the case of depression, the total score improved by 45% by means of Biogena Griffonia50 Serolution®, in the placebo group by 22%.
  • The total score for anxiety reduced by 63% in the Griffonia group, contrary to 34% in the placebo group.
  • The result is quite similar for the stress score: Here, the Griffonia group improved by 50%, the placebo group by 39%.
  • By the way, the improvements for moods and anxiety are considered scientifically significant, which means that the effect of Griffonia is more than just a coincidence.
  • The authors of the study
    Director of the study: Dr. med. Walter Wührer, General practitioner, Salzburg
    Dr. Ina Viebahn, nutritionist Biogena Scientific Team, coordination scientific studies
    Barbara Fäth-Neubauer (Dipl. oec. troph. Univ.) nutritionist, Director of Biogena Scientific Team